{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=control+condition&page=20",
    "query": {
      "intervention": "control condition",
      "page": 20
    },
    "page_size": 10
  },
  "pagination": {
    "page": 20,
    "page_size": 10,
    "total_count": 12606,
    "total_pages": 1261,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=control+condition&page=21&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=control+condition&page=19&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-20T01:59:40.606Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01885559",
      "title": "HALT Progression of Polycystic Kidney Disease Study B",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Kidney, Polycystic"
      ],
      "interventions": [
        {
          "name": "Lisinopril",
          "type": "DRUG"
        },
        {
          "name": "Telmisartan",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "15 Years",
        "maximum_age": "64 Years",
        "sex": "ALL",
        "summary": "15 Years to 64 Years"
      },
      "enrollment_count": 486,
      "start_date": "2006-01",
      "completion_date": "2014-06",
      "has_results": true,
      "last_update_posted_date": "2020-04-22",
      "last_synced_at": "2026-11-20T01:59:40.606Z",
      "location_count": 7,
      "location_summary": "Aurora, Colorado • Atlanta, Georgia • Kansas City, Kansas + 3 more",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Kansas City",
          "state": "Kansas"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01885559"
    },
    {
      "nct_id": "NCT02327559",
      "title": "Prenatal Education About Reducing Labor Stress (PEARLS)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Labor Pain",
        "Tocophobia"
      ],
      "interventions": [
        {
          "name": "Mind in Labor (MIL): Working with Pain in Childbirth",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Treatment as usual (TAU)",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "University of California, San Francisco",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 33,
      "start_date": "2011-10",
      "completion_date": "2015-02",
      "has_results": false,
      "last_update_posted_date": "2017-05-25",
      "last_synced_at": "2026-11-20T01:59:40.606Z",
      "location_count": 1,
      "location_summary": "San Francisco, California",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02327559"
    },
    {
      "nct_id": "NCT01131559",
      "title": "Adjunctive Lisdexamfetamine (LDX) in Bipolar Depression",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Bipolar",
        "Depression"
      ],
      "interventions": [
        {
          "name": "Lisdexamfetamine",
          "type": "DRUG"
        },
        {
          "name": "Placebo control",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Lindner Center of HOPE",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 50,
      "start_date": "2010-01",
      "completion_date": "2014-02",
      "has_results": false,
      "last_update_posted_date": "2014-03-05",
      "last_synced_at": "2026-11-20T01:59:40.606Z",
      "location_count": 1,
      "location_summary": "Mason, Ohio",
      "locations": [
        {
          "city": "Mason",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01131559"
    },
    {
      "nct_id": "NCT03473223",
      "title": "Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Acute Coronary Syndrome"
      ],
      "interventions": [
        {
          "name": "Apolipoprotein A-I [human] (apoA-I)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "CSL Behring",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 18226,
      "start_date": "2018-03-21",
      "completion_date": "2023-11-17",
      "has_results": true,
      "last_update_posted_date": "2025-01-14",
      "last_synced_at": "2026-11-20T01:59:40.606Z",
      "location_count": 202,
      "location_summary": "Alexander City, Alabama • Birmingham, Alabama • Huntsville, Alabama + 175 more",
      "locations": [
        {
          "city": "Alexander City",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Gilbert",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03473223"
    },
    {
      "nct_id": "NCT00143091",
      "title": "Multicentre Trial to Evaluate the Safety and Efficacy of CP-316,311 in Major Depressive Disorder",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Depressive Disorder, Major"
      ],
      "interventions": [
        {
          "name": "CP-316,311",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Sertraline",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 200,
      "start_date": "2005-04",
      "completion_date": "2006-04",
      "has_results": false,
      "last_update_posted_date": "2008-03-24",
      "last_synced_at": "2026-11-20T01:59:40.606Z",
      "location_count": 2,
      "location_summary": "Bellevue, Washington • Seattle, Washington",
      "locations": [
        {
          "city": "Bellevue",
          "state": "Washington"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00143091"
    },
    {
      "nct_id": "NCT01059474",
      "title": "Transdermal Absorption of Dimercaptopropane-1-Sulfonate (DMPS) and Effect on Urinary Mercury Excretion",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Toxicity"
      ],
      "interventions": [
        {
          "name": "transdermal DMPS",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Banner Health",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 9,
      "start_date": "2010-04",
      "completion_date": "2010-12",
      "has_results": false,
      "last_update_posted_date": "2011-06-22",
      "last_synced_at": "2026-11-20T01:59:40.606Z",
      "location_count": 1,
      "location_summary": "Phoenix, Arizona",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01059474"
    },
    {
      "nct_id": "NCT05386355",
      "title": "Improving Pediatric COVID-19 Vaccine Uptake Using an mHealth Tool",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "COVID-19 Vaccines",
        "Telemedicine",
        "Vaccine Hesitancy",
        "Pediatric ALL"
      ],
      "interventions": [
        {
          "name": "COVID-19 Vaccine Uptake App",
          "type": "BEHAVIORAL"
        },
        {
          "name": "General Health App",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL",
        "OTHER"
      ],
      "sponsor": "IDeA States Pediatric Clinical Trials Network",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1934,
      "start_date": "2022-07-18",
      "completion_date": "2023-09-25",
      "has_results": true,
      "last_update_posted_date": "2025-03-11",
      "last_synced_at": "2026-11-20T01:59:40.606Z",
      "location_count": 15,
      "location_summary": "Little Rock, Arkansas • Wilmington, Delaware • Honolulu, Hawaii + 12 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Wilmington",
          "state": "Delaware"
        },
        {
          "city": "Honolulu",
          "state": "Hawaii"
        },
        {
          "city": "Kansas City",
          "state": "Kansas"
        },
        {
          "city": "Louisville",
          "state": "Kentucky"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05386355"
    },
    {
      "nct_id": "NCT02954978",
      "title": "Impact of Nilotinib on Safety, Tolerability, Pharmacokinetics and Biomarkers in Parkinson's Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Parkinson Disease",
        "Parkinsons Disease With Dementia"
      ],
      "interventions": [
        {
          "name": "Placebo Oral Capsule",
          "type": "DRUG"
        },
        {
          "name": "Nilotinib 150mg oral capsule [Tasigna]",
          "type": "DRUG"
        },
        {
          "name": "Nilotinib 300mg oral capsule [Tasigna]",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Georgetown University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "40 Years to 90 Years"
      },
      "enrollment_count": 75,
      "start_date": "2017-01",
      "completion_date": "2020-07",
      "has_results": true,
      "last_update_posted_date": "2026-06-12",
      "last_synced_at": "2026-11-20T01:59:40.606Z",
      "location_count": 1,
      "location_summary": "Washington D.C., District of Columbia",
      "locations": [
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02954978"
    },
    {
      "nct_id": "NCT07656415",
      "title": "A Study to Investigate the Effect of Mitapivat on Transfusion Burden in Subjects With Sickle Cell Disease (SCD)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Sickle Cell Disease"
      ],
      "interventions": [
        {
          "name": "Mitapivat Matched Placebo",
          "type": "DRUG"
        },
        {
          "name": "Mitapivat",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Agios Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 159,
      "start_date": "2026-07-21",
      "completion_date": "2030-08",
      "has_results": false,
      "last_update_posted_date": "2026-10-28",
      "last_synced_at": "2026-11-20T01:59:40.606Z",
      "location_count": 5,
      "location_summary": "Indianapolis, Indiana • Grand Rapids, Michigan • Flowood, Mississippi + 2 more",
      "locations": [
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Grand Rapids",
          "state": "Michigan"
        },
        {
          "city": "Flowood",
          "state": "Mississippi"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07656415"
    },
    {
      "nct_id": "NCT04884815",
      "title": "A Phase 1/2/3 Study of UX701 Gene Therapy in Adults With Wilson Disease",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Wilson Disease"
      ],
      "interventions": [
        {
          "name": "UX701",
          "type": "GENETIC"
        },
        {
          "name": "Standard of Care (SOC)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "GENETIC",
        "DRUG"
      ],
      "sponsor": "Ultragenyx Pharmaceutical Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 82,
      "start_date": "2021-09-27",
      "completion_date": "2034-03",
      "has_results": false,
      "last_update_posted_date": "2026-09-25",
      "last_synced_at": "2026-11-20T01:59:40.606Z",
      "location_count": 12,
      "location_summary": "Los Angeles, California • Redwood City, California • Sacramento, California + 9 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Redwood City",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04884815"
    }
  ]
}